CeloNova BioSciences, Inc.
CeloNova BioSciences, Inc. is an innovative global medical device leader transforming the treatment of cardiovascular disease and addressing the treatment gap in patients at high risk of bleeding. CeloNova BioSciences develops, manufactures and markets a family of products based upon its novel Polyzene-F nanocoating technology. This next-generation nanocoating is the result of years of rigorous scientific research and German-engineering and has been widely published in numerous academic articles to date. In 2015, CeloNova BioSciences interventional radiology product lines were acquired by Boston Scientific. Read more here. Moving forward, CeloNova BioSciences is looking to develop new PzF applications for implantable medical devices that will help patients and change the practice of medicine around the world.
In January 2018, CeloNova became one of a handful of companies in the U.S. selected to support advancements in medical device quality and safety through partnership with the FDA’s Case for Quality Voluntary Improvement Program (CFQ VIP).
This program identifies device manufacturers that consistently produce high-quality devices to help better focus FDA resources and promote best practices to help other manufacturers raise their level of quality and safety. Through the program’s partnership, CeloNova aims to further advance quality of care in patients in the U.S. 1
CeloNova was recently featured in a case study by the CMMI Institute for our dedication to compliance and quality, and you can read more about our journey and success by reading the full CMMI CeloNova Case Study, and also in a recent CMMI blog post.
In April of 2019, MedTech Outlook recognizes CeloNova BioSciences, Inc. as a pioneer at the forefront of cardiovascular innovation by naming the company as one of the top 10 cardiovascular companies of 2019.
CeloNova’s foundation of innovation has led to the successful manufacturing and marketing of a family of products, including the COBRA PzF NanoCoated Coronary Stent (NCS), based upon its proprietary Polyzene-F (PzF) nanocoating technology, a revolutionary surface coating designed to optimize implant interaction within the body.Through its commitment to PzF innovation, CeloNova is transforming clinical practice and promoting positive outcomes in patients around the world.
CeloNova BioSciences Inc. is committed to high standards of compliance and ethics. CeloNova abides by the Advanced Medical Technology Association (AdvaMed) Code of Ethics on Interactions with Health Care Professionals, which provides a guide for ethical and lawful business practices for the medical technology industry. CeloNova’s compliance program is established to prevent and detect violations of the AdvaMed code, company policies, and applicable laws. The complete AdvaMed Code of Ethics can be found HERE.